Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Autores principales: Chen, Ting, Wang, Changyuan, Liu, Qi, Meng, Qiang, Sun, Huijun, Huo, Xiaokui, Sun, Pengyuan, Peng, Jinyong, Liu, Zhihao, Yang, Xiaobo, Liu, Kexin
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2014
Materias:
Research Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622436/
https://ncbi.nlm.nih.gov/pubmed/25482933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987062
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares